Recent FATE News
- Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus • GlobeNewswire Inc. • 12/09/2024 09:01:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/03/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 07:33:53 PM
- Fate Therapeutics Announces Leadership Transition • GlobeNewswire Inc. • 11/29/2024 06:05:00 PM
- Fate Therapeutics to Present at Upcoming December Investor Conferences • GlobeNewswire Inc. • 11/26/2024 09:01:00 PM
- Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence • GlobeNewswire Inc. • 11/18/2024 01:05:00 PM
- Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence • GlobeNewswire Inc. • 11/18/2024 01:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:50:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 09:01:59 PM
- Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 11/12/2024 09:01:00 PM
- Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting • GlobeNewswire Inc. • 11/09/2024 06:30:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/08/2024 10:31:15 PM
- Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting • GlobeNewswire Inc. • 11/08/2024 09:01:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/04/2024 09:01:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/26/2024 01:37:07 AM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/02/2024 08:01:00 PM
- Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/12/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:21:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 08:26:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:08:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:06:21 PM
- Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM